Effect of Kinesio Taping and Extracorporeal Shock Wave Therapy on Plantar Fasciitis
NCT ID: NCT06055933
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2023-10-02
2023-12-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To compare the acute effect of pain level, lower extremity functionality level and plantar fascia flexibility in patients with plantar fasciitis who received KT application in addition to ESWT treatment.
To compare the acute effect of pain level, lower extremity functionality level and plantar fascia flexibility in patients with plantar fasciitis receiving placebo application.
90 volunteers will be included in the study as ESWT (n=30), placebo ESWT (n=30), ESWT and KT (n=30) application groups. How effective is ESWT, ESWT and Kinesiotape versus placebo ESWT acutely in the treatment of plantar fasciitis?
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Age (years), height (cm) and body weight (kg) measured with an adult scale with a mechanical height measure, gender, occupation, affected side and dominant side of patients diagnosed with plantar fasciitis will be recorded.
Patients will be divided into three groups: ESWT (Group 1), ESWT and KT (Group 2), and Placebo/Sham (Group 3) application groups. ESWT (BTL-6000SWT, UK); A single session will be applied at 10 Hz frequency, 2.5 Barr energy and 2000 shocks/session.
For KT application, a tape consisting of 96% cotton, 4% lycra, water-resistant, porous and adhesive, 5 cm wide and 0.5 mm thick will be used. Taping will be done after the ESWT session and the tape will be asked to remain for a week. After the first examination of the physical therapy and rehabilitation specialist physician in the placebo/Sham group, the patient will be listened to the sound of the device through the audio device and ESWT application will be applied without the device working.
For clinical follow-up of the patients, visual pain scale (VAS) score, lower extremity functional scale score will be used before and one week after treatment, and plantar fascia flexibility will be evaluated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESWT
To the ESWT group, with the ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shock/session values was applied with a 15 mm head in a single session. Shock waves were applied directly to the most sensitive point detected in the medial of the calcaneus.
No interventions assigned to this group
Placebo ESWT
The placebo ESWT group was given the ESWT device sound recorded from the external audio device and the application was performed without the ESWT device operating.
No interventions assigned to this group
ESWT+KT
With ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shocks/session was applied in a single session with a 15 mm head. Shock waves will be applied directly to the most sensitive point detected in the medial calcaneus, then a tape consisting of 96% cotton and 4% lycra, water-resistant, porous and adhesive, 5 cm wide and 0.5 mm thick will be used. Taping will be done after the ESWT session and the tape will be asked to remain for a week.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cases willing to continue the study,
* In the anamnesis, cases with severe pain when taking the first step after waking up in the morning or after a long period of inactivity and progressive aggravation of the pain as the activity continues,
* Cases whose consent forms were obtained by being informed about the study.
Exclusion Criteria
* Loss or decrease of sensation in the foot and ankle region for various reasons,
* Difficulty in communication that prevents treatment and evaluations from being carried out effectively,
* Pregnancy,
* Presence of local infection,
* Having a widespread or regional tumoral disease,
* Having circulatory disorders in the lower extremities, bleeding,
* Anticoagulant use,
* Application of other treatment methods such as cold/hot application, exercise, orthosis use, electrotherapy agents,
* Cases with a history of systemic, inflammatory, neurological or vascular disease.
18 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Necmettin Erbakan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abdulkadir dağbaşı
physiotherapist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hanife Doğan
Role: PRINCIPAL_INVESTIGATOR
Necmettin Erbakan University
abdulkadir dağbaşı
Role: STUDY_CHAIR
Necmettin Erbakan University
Aynur Başaran
Role: STUDY_CHAIR
Karamanoğlu Mehmetbey University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Necmettin Erbakan Üniversitesi
Konya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADagbasi001
Identifier Type: -
Identifier Source: org_study_id